DeepMind Blog
May 16
Uncovering repurposed medicines to fight liver fibrosis
Stanford geneticist uses Co-Scientist to help find new treatments for chronic liver disease and liver fibrosis.
Accelerating the development of life-saving treatments
Accelerating the development of life-saving treatments.
Related stories
OpenAI Blog
Aug 22, 2025
Accelerating life sciences research
Discover how a specialized AI model, GPT-4b micro, helped OpenAI and Retro Bio engineer more effective proteins for stem cell therapy and longevity research.
arXiv Computation and Language
Sep 21
TrialAtlas: Multi-Agent Research Organization for Clinical Trial Design and Optimization
arXiv:2609.21859v1 Announce Type: new Abstract: Nearly 90% of drugs entering clinical development ultimately fail, despite billions of dollars in investment. Pharmaceutical companies therefore rely o...
arXiv AI
Sep 7
Model Retirement Creates Reproducibility Risk in Biomedical AI Publications
The study examined biomedical research articles from 2022 to March 2026 that employed large language models (LLMs). It found that 42% of the most frequently used models were already retired or scheduled to retire within two years of publication, with a median retirement interval of 538 days. This high rate of model deprecation threatens the reproducibility of biomedical AI research.
OpenAI Blog
Jun 3
Introducing new capabilities to GPT-Rosalind
GPT-Rosalind advances life sciences research with enhanced biological reasoning, medicinal chemistry expertise, genomics analysis, and experimental workflow capabilities.
OpenAI Blog
Apr 16
Introducing GPT-Rosalind for life sciences research
OpenAI introduces GPT-Rosalind, a frontier reasoning model built to accelerate drug discovery, genomics analysis, protein reasoning, and scientific research workflows.
arXiv AI
Jul 7
A Precedent-Guided Co-Scientist for Side-Effect-Aware Drug Redesign
arXiv:2607. 02944v1 Announce Type: cross Abstract: We propose PRECEDE, a precedent-guided co-scientist for side-effect-aware drug redesign that revises a parent compound to mitigate a specified side effect while preserving therapeutic function.
arXiv Machine Learning
Jul 24
A Diffusion-Model Subpopulation Digital Twin for Mobile Health Deployment: A Case Study on the HeartSteps Intervention
arXiv:2607. 21403v1 Announce Type: new Abstract: Mobile-health interventions increasingly use online learning and decision making algorithms to personalize when to nudge users toward healthier behavior, but a poorly designed algorithm can burden and disengage participants.
DeepMind Blog
May 16
Opening new paths in aging research
Calico Life Sciences uses Co-Scientist to connect scattered findings and generate new leads in aging research.
arXiv AI
Jun 8
Exploring Reinforcement Learning for Fluid Transitions Between Clinical Mental Healthcare and Everyday Wellness Support
arXiv:2606. 06800v1 Announce Type: cross Abstract: Mental health struggles wax and wane, yet clinical and wellness interventions typically operate separately, causing frequent breakdowns at care transitions.
DeepMind Blog
May 18
Fast-tracking genetic leads to reverse cellular aging
Biologists use Co-Scientist to find novel factors that successfully rejuvenate human cells.
OpenAI Blog
Jun 17
Introducing LifeSciBench
Introducing LifeSciBench, an expert-authored, expert-reviewed benchmark for evaluating how AI systems handle real-world life science research tasks and decisions.